Agents to target activating FcγR signaling might be of utility and include Syk (spleen tyrosine kinase) inhibitors, which are currently being assessed in rheumatoid arthritis (Weinblatt et al., 2010) and glomerulonephritis (Ma et al., 2017). The gene discussed is FCGR2A; the disease is glomerulonephritis.